Ablynx receives €1.2 million grant to further advance its anti-IL-6R programme, ALX-0061
Ablynx announced that it has been awarded a grant worth €1.2 million by the Flemish agency for Innovation by Science and Technology (IWT).
The grant supports Ablynx in accelerating the development of its Nanobody-based programme, ALX-0061, into clinical development for the treatment of autoimmune and inflammatory diseases.
ALX-0061 binds to the IL-6 receptor (IL-6R). It has a high potency and demonstrated a favourable pharmacodynamic (PD), pharmacokinetic (PK) and safety profile in pre-clinical testing compared with the benchmark molecule. ALX-0061 has no Fc-mediated effector function which may translate into an improved safety profile. Due to its monovalent binding to the target, it also does not have the potential to crosslink the IL-6R target which may have some benefits compared with monoclonal antibody approaches.
Most read news
Other news from the department research and development
Get the life science industry in your inbox
From now on, don't miss a thing: Our newsletter for biotechnology, pharma and life sciences brings you up to date every Tuesday and Thursday. The latest industry news, product highlights and innovations - compact and easy to understand in your inbox. Researched by us so you don't have to.